Nestlé buys the rest of Aimmune, aiming to boost a struggling peanut allergy treatment

Bio Pharma Dive

The Swiss firm will take over the launch of Aimmune's Palforzia, sales of which have disappointed since its approval in January

Nestlé to acquire Aimmune Therapeutics, growing food allergy portfolio

BioPharma Reporter

Swiss giant Nestlà is to acquire Aimmune Therapeutics, a biopharmaceutical company developing and commercializing treatments for food allergies. Aimmuneâs Palforzia is the worldâs first approved treatment for peanut allergy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FDA rejects a peanut allergy treatment, sinking a small biotech's shares

Bio Pharma Dive

Given the long list of requirements in the FDA's rejection letter, DBV Technologies likely has years of work ahead to win approval of Viaskin Peanut

Gene variants help explain connection between skin disorder and food allergy risk

Scienmag

Medicine & Health Dermatology Genetics Immunology/Allergies/Asthma Medicine/Health Pediatrics

Spectrum Veterinary Integrates Revolutionary New Testing Reagent to Its Allergy Testing Technology That Reduces False-Positive Results for Pet Allergies

BioTech 365

leader in companion-animal allergy testing and treatment, has incorporated a new blocking reagent to advance its already fully automated allergy-testing process. The reagent addresses naturally occurring cross-reactive carbohydrate determinants (CCDs) that result in false-positive allergy … Continue reading → Business WirePHOENIX–(BUSINESS WIRE)–#nextmune–Spectrum Veterinary, the U.S.

Latitude Expands Innovative Food Allergy Care to Families Across the Bay Area

BioTech 365

Pioneering a new standard of food allergy care, Latitude takes the next step towards building a national network of its specialized clinics and services REDWOOD CITY, Calif.–(BUSINESS

Allergy Immunotherapies Market – Actionable Research on COVID-19 | Increasing Prevalence of Allergies to Boost the Market Growth | Technavio

BioTech 365

LONDON–(BUSINESS WIRE)–#AllergyImmunotherapiesMarket–The global allergy immunotherapies market size is poised to grow by USD 626.77 million during 2020-2024, progressing at a CAGR of about 7% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date … Continue reading → Business Wire

Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers

BioTech 365

LONDON–(BUSINESS WIRE)–Aimmune Therapeutics, Inc.

Camallergy Chief Medical Officer Receives Distinguished Award from British Allergy Society

BioTech 365

-BSACI honours Dr Andrew Clark with William Frankland Award for outstanding contributions to clinical allergy CAMBRIDGE, England–(BUSINESS WIRE)–#anaphylaxis–Cambridge Allergy Ltd (“Camallergy” or “the Company”), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced the … Continue reading → Business Wire

DBV craters on FDA’s peanut allergy immunotherapy rejection

Pharma Phorum

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. million people with peanut allergy in the US, one million of them under the age of 18.

Aimmune’s peanut allergy med moves toward EU approval

Pharma Times

CHMP grants Palforzia a positive opinion for the treatment of peanut allergic patients

FDA Issues CRL for DBV Technologies' Viaskin Peanut Allergy Patch

BioSpace

In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications

IgGenix Launches with $10 Million to Develop Therapeutics for Severe Allergies

BioSpace

emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions Startup IgGenix, Inc.

Global Ragweed Pollen Allergy Treatment Market to be valued at US$ 1,147.3 Million by 2027, Says Coherent Market Insights (CMI)

BioTech 365

SEATTLE–(BUSINESS WIRE)–#RagweedPollenAllergyTreatment–According to Coherent Market Insights, the global ragweed pollen allergy treatment market is estimated to be valued at US$ 836.9

Allergy Rhinitis Drugs Market – Actionable Research on COVID-19 | Growing Awareness about Allergic Rhinitis to Boost the Market Growth | Technavio

BioTech 365

LONDON–(BUSINESS WIRE)–#AllergyRhinitisDrugsMarket–The global allergy rhinitis drugs market size is poised to grow by USD 2.4 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio. The report offers an … Continue reading → Business Wire

Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target

Delveinsight

FDA turns back peanut allergy patch of DBV Technologies. A peanut allergy patch which is based on new delivery technology has hit a snag at the FDA. Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test.

Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

BioTech 365

— Final Day 29 Data Show Superior Efficacy of Veklury Compared with Placebo in Hospitalized Patients Receiving Standard of Care — — Overall, Treatment with Veklury Resulted in Five Days Faster Recovery and Reduced Disease Progression Compared with Placebo — … Continue reading → Business Wire

Nestle makes newly acquired Aimmune a stand-alone unit, appoints new CEO

Bio Pharma Dive

Andrew Oxtoby, formerly chief commercial officer at the peanut allergy drugmaker, will take over as head of the new Nestle business

CBD helps reduce lung damage from COVID by increasing levels of protective peptide

Scienmag

Biology Cell Biology Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Pulmonary/Respiratory Medicine Virology

Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market

BioTech 365

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS –(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.

EU approves new indication for Novartis’ Xolair

Pharma Times

Allergy drug approved for severe chronic rhinosinusitis with nasal polyps

Could an existing vaccine make COVID-19 less deadly? Mexico City study provides support

Scienmag

A prospective observational study testing the concept of trained immunity for protection from severe COVID-19 reported milder symptoms in COVID patients receiving MMR vaccination, as published in Allergy.

Attend the 2020 ACAAI Annual Scientific Meeting from where you are sitting right now

Scienmag

This year’s groundbreaking allergy and asthma news will be delivered virtually, and for free. Every year you rely on the American College of Allergy, Asthma and Immunology’s Annual Scientific Meeting to deliver the most recent updates on what is happening in the world of allergy and asthma research and treatment. Medicine & Health Immunology/Allergies/Asthma

New imaging method reveals HIV’s sugary shield in unprecedented detail

Scienmag

Medicine & Health Cell Biology Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health VirologyThe technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Could BCG vaccine protect against COVID-19? UK recruitment begins

Scienmag

Medicine & Health Grants/Funding Health Professionals Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Public Health

NIH award to fuse immunology and neuroscience research

Scienmag

Medicine & Health Endocrinology Immunology/Allergies/Asthma Medicine/Health NeurobiologyCredit: Virginia Tech Gabriela Carrillo didn’t always aspire to be a neuroscientist.

Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors

Scienmag

Cancer cancer Clinical Trials Gastroenterology Genes Genetics Immunology/Allergies/Asthma Medicine/Health Pulmonary/Respiratory Medicine Urogenital SystemLatest results from KRYSTAL-1 early clinical trial of adagrasib (MRTX849) Credit: Pasi A.

Gene 56

New study reveals why flu can be devastating for pregnant women

Scienmag

Infectious Emerging Diseases Developmental/Reproductive Biology Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Virology

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered

Scienmag

Cancer Bacteriology cancer Cardiology Dentistry/Periodontal Disease Immunology/Allergies/Asthma Medicine/Health Microbiology

Study identifies key enzyme for development of autoimmune diseases

Scienmag

Chemistry AND Physics Aging Immunology/Allergies/Asthma Medicine/Health Neurobiology Pharmaceutical SciencesAn enzyme associated with energy production in cells also participates in the differentiation of immune cells involved in exacerbated inflammation.

Enzyme biofactories to enhance cord blood transplants

Scienmag

Medicine & Health Biochemistry Biomedical/Environmental/Chemical Engineering Biotechnology Immunology/Allergies/Asthma Medicine/Health Molecular Biology

Study connects hormones we’re born with to lifetime risk for immunological diseases

Scienmag

Cancer cancer Genetics Immunology/Allergies/Asthma Internal Medicine Medicine/Health Metabolism/Metabolic Diseases Microbiology Sex-Linked Conditions

Protein produced by the nervous system may help treatments for inflammatory diseases

Scienmag

Rutgers researchers discovered a new role the protein may have in helping to treat allergies, asthma, COPD A Rutgers-led team may have found the key to treating inflammatory diseases like asthma, allergies, chronic fibrosis and chronic obstructive pulmonary disease (COPD). Medicine & Health Cell Biology Immunology/Allergies/Asthma Medicine/Health

Immune cell activation in severe COVID-19 resembles lupus

Scienmag

Medicine & Health Cell Biology Critical Care/Emergency Medicine Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Pulmonary/Respiratory MedicineExtrafollicular B cell pathway In severe cases of COVID-19, Emory researchers have been observing an exuberant activation of immune cells, resembling acute flares of systemic lupus erythematosus (SLE), an autoimmune disease.

Immune activation in the liver illuminated with new glycan-tagging strategy

Scienmag

Chemistry AND Physics Biochemistry Biology Biomedical/Environmental/Chemical Engineering Biotechnology Cell Biology Immunology/Allergies/Asthma Internal Medicine Liver Molecular Biology

CNIO team finds how melanoma ‘deceives’ the immune system, increasing resistance to immunotherapy

Scienmag

Technology and Engineering Biology Biomedical/Environmental/Chemical Engineering Biotechnology cancer Dermatology Genes Genetics Immunology/Allergies/Asthma Medicine/Health Molecular BiologyCredit: A.

Natural killer cells also have a memory function

Scienmag

Biology Immunology/Allergies/Asthma Medicine/Health Molecular Biology

Protein that keeps immune system from freaking out could form basis for new therapeutics

Scienmag

Chemistry AND Physics Bacteriology Biochemistry Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Microbiology Molecular Biology

Computer model shows how COVID-19 could lead to runaway inflammation

Scienmag

Biology Critical Care/Emergency Medicine Genetics Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Molecular Biology Pediatrics Toxicology VirologyCredit: Serkan Eldeleklio?lu lu PITTSBURGH, Sept.

New population of immune cells could play a role in multiple sclerosis

Scienmag

Biology Immunology/Allergies/AsthmaResearchers uncover defining features of a subset of T-cells that may drive autoimmunity in MS, and could prove to be a new target for therapy. PHILADELPHIA – Multiple sclerosis (MS) is an autoimmune disorder that develops as immune cells attack the nervous system. T cells are a critical part of our immune system, with a […].